Top news from MedWatch this week

Monday
Leo Pharma awaiting final decision on antibody after phase II defeat
Zevra to finish what Orphazyme started: ”We have set ourselves up for success”
Tuesday
Leo Pharma cleaves R&D organization, hires veteran dermatologist to lead early development
Novo Nordisk: Life science power in EU industrial policy revision has been dimmed by Brexit
Wednesday
Departing GN chair: An organizational split would be unwise
New GN chair wants to find debt solution – but can’t say when
Thursday
UK pharma group suspends Novo Nordisk for two years
EU weighs plan to incentivize drugmakers to fight superbugs
Friday
Novo Nordisk reacts to suspension: ”We take the decision very seriously”
GN’s scrapped capital raise: Norges Bank voted no, William Demant Invest abstained